Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tailored Operative or Non-operative Management for MRI Defined Low-risk Rectal Cancer Following Neoadjuvant Intensity Modulated Radiotherapy With Concurrent Capecitabine Plus Consolidation CapeOX.

NCT02860234 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT02860234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02860234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tailored Operative or Non-operative Management for MRI Defined Low-risk Rectal Cancer Following Neoadjuvant Intensity Modulated Radiotherapy With Concurrent Capecitabine Plus Consolidation CapeOX.
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Observational
Overall status
Completed
Start date
August 31, 2016
Completion date
November 30, 2019
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer